REVLIMID, BENDAMUSTINE AND PREDNISOLONE (RBP) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS OF A PHASE II CLINICAL TRIAL; OSHO – #077
(Abstract release date: 05/19/16)
EHA Library. Beck J. 06/09/16; 132865; E1316
Mrs. Juliane Beck
Contributions
Contributions
Abstract
Abstract: E1316
Type: Eposter Presentation
Background
While the role of lenalidomide monotherapy in the treatment of relapsed/refractory patients with multiple myeloma (MM) is well established, combination therapies with lenalidomide are still under investigation in many phase 2/3 studies.
Aims
In the current study, a combination therapy of lenalinomide (Revlimid®), bendamustine and prednisolone (RBP) was tested in patients with relapsed or refractory MM.
Methods
In the previously completed phase 1 study RPB with a dose of 25 mg lenalidomide d 1-21 and 75 mg/m² bendamustine d 1-2 was well tolerated in patients with relapsed/refractory MM (Pönisch et al. 2013). The treatment was repeated every 28 days for a maximum of eight cycles. Thereafter, patients received a maintenance therapy with 10 mg lenalidomide over 10 cycles.
Results
25 patients (19 patients of the phase 2 study and additional 6 patients from the highest dose level of the phase 1 study) were included in this analysis. Twenty two patients (88%) responded after at least two cycles of RBP with 1 sCR, 5 nCR, 8 VGPR and 8 PR. Due to increased haematological toxicity a dose reduction was required in subsequent therapy cycles in the most of all patients. 19 patients discontinued the treatment prematurely due to a stem cell transplantation (n=7), hematological toxicity (n=7), non hematological toxicity (n=3) or progress (n=2). The median progression-free and overall survival was 22 and 38 months, respectively.
Conclusion
RBP is a highly effective therapy for patients with relapsed or refractory MM. However, dose reduction is necessary in many patients because an increased haematological toxicity rate.
Session topic: E-poster
Keyword(s): Bendamustine, Imids, Multiple myeloma
Type: Eposter Presentation
Background
While the role of lenalidomide monotherapy in the treatment of relapsed/refractory patients with multiple myeloma (MM) is well established, combination therapies with lenalidomide are still under investigation in many phase 2/3 studies.
Aims
In the current study, a combination therapy of lenalinomide (Revlimid®), bendamustine and prednisolone (RBP) was tested in patients with relapsed or refractory MM.
Methods
In the previously completed phase 1 study RPB with a dose of 25 mg lenalidomide d 1-21 and 75 mg/m² bendamustine d 1-2 was well tolerated in patients with relapsed/refractory MM (Pönisch et al. 2013). The treatment was repeated every 28 days for a maximum of eight cycles. Thereafter, patients received a maintenance therapy with 10 mg lenalidomide over 10 cycles.
Results
25 patients (19 patients of the phase 2 study and additional 6 patients from the highest dose level of the phase 1 study) were included in this analysis. Twenty two patients (88%) responded after at least two cycles of RBP with 1 sCR, 5 nCR, 8 VGPR and 8 PR. Due to increased haematological toxicity a dose reduction was required in subsequent therapy cycles in the most of all patients. 19 patients discontinued the treatment prematurely due to a stem cell transplantation (n=7), hematological toxicity (n=7), non hematological toxicity (n=3) or progress (n=2). The median progression-free and overall survival was 22 and 38 months, respectively.
Conclusion
RBP is a highly effective therapy for patients with relapsed or refractory MM. However, dose reduction is necessary in many patients because an increased haematological toxicity rate.
Session topic: E-poster
Keyword(s): Bendamustine, Imids, Multiple myeloma
Abstract: E1316
Type: Eposter Presentation
Background
While the role of lenalidomide monotherapy in the treatment of relapsed/refractory patients with multiple myeloma (MM) is well established, combination therapies with lenalidomide are still under investigation in many phase 2/3 studies.
Aims
In the current study, a combination therapy of lenalinomide (Revlimid®), bendamustine and prednisolone (RBP) was tested in patients with relapsed or refractory MM.
Methods
In the previously completed phase 1 study RPB with a dose of 25 mg lenalidomide d 1-21 and 75 mg/m² bendamustine d 1-2 was well tolerated in patients with relapsed/refractory MM (Pönisch et al. 2013). The treatment was repeated every 28 days for a maximum of eight cycles. Thereafter, patients received a maintenance therapy with 10 mg lenalidomide over 10 cycles.
Results
25 patients (19 patients of the phase 2 study and additional 6 patients from the highest dose level of the phase 1 study) were included in this analysis. Twenty two patients (88%) responded after at least two cycles of RBP with 1 sCR, 5 nCR, 8 VGPR and 8 PR. Due to increased haematological toxicity a dose reduction was required in subsequent therapy cycles in the most of all patients. 19 patients discontinued the treatment prematurely due to a stem cell transplantation (n=7), hematological toxicity (n=7), non hematological toxicity (n=3) or progress (n=2). The median progression-free and overall survival was 22 and 38 months, respectively.
Conclusion
RBP is a highly effective therapy for patients with relapsed or refractory MM. However, dose reduction is necessary in many patients because an increased haematological toxicity rate.
Session topic: E-poster
Keyword(s): Bendamustine, Imids, Multiple myeloma
Type: Eposter Presentation
Background
While the role of lenalidomide monotherapy in the treatment of relapsed/refractory patients with multiple myeloma (MM) is well established, combination therapies with lenalidomide are still under investigation in many phase 2/3 studies.
Aims
In the current study, a combination therapy of lenalinomide (Revlimid®), bendamustine and prednisolone (RBP) was tested in patients with relapsed or refractory MM.
Methods
In the previously completed phase 1 study RPB with a dose of 25 mg lenalidomide d 1-21 and 75 mg/m² bendamustine d 1-2 was well tolerated in patients with relapsed/refractory MM (Pönisch et al. 2013). The treatment was repeated every 28 days for a maximum of eight cycles. Thereafter, patients received a maintenance therapy with 10 mg lenalidomide over 10 cycles.
Results
25 patients (19 patients of the phase 2 study and additional 6 patients from the highest dose level of the phase 1 study) were included in this analysis. Twenty two patients (88%) responded after at least two cycles of RBP with 1 sCR, 5 nCR, 8 VGPR and 8 PR. Due to increased haematological toxicity a dose reduction was required in subsequent therapy cycles in the most of all patients. 19 patients discontinued the treatment prematurely due to a stem cell transplantation (n=7), hematological toxicity (n=7), non hematological toxicity (n=3) or progress (n=2). The median progression-free and overall survival was 22 and 38 months, respectively.
Conclusion
RBP is a highly effective therapy for patients with relapsed or refractory MM. However, dose reduction is necessary in many patients because an increased haematological toxicity rate.
Session topic: E-poster
Keyword(s): Bendamustine, Imids, Multiple myeloma
{{ help_message }}
{{filter}}